Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tuberculosis vaccine H4IC - AJ Vaccines

Drug Profile

Tuberculosis vaccine H4IC - AJ Vaccines

Alternative Names: Adjuvanted TB subunit vaccine H4IC - AJ Vaccines/sanofi pasteur; AERAS-404; Ag85B-TB10.4-IC31; H4+IC31; H4/AERAS-404+IC31®; H4/IC31 vaccine; H4:IC31; HyVac4; HyVac4-IC31; Tuberculosis vaccine H4IC - AJ Vaccines/sanofi pasteur

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Statens Serum Institut
  • Developer Aeras; AJ Vaccines; National Institute of Allergy and Infectious Diseases; Sanofi Pasteur
  • Class Adjuvants; Antituberculars; Recombinant fusion proteins; Subunit vaccines; Synthetic vaccines; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in Tuberculosis in Netherlands (IM, Injection)
  • 28 Oct 2019 No recent reports of development identified for phase-I development in Tuberculosis(Prevention) in Switzerland (IM, Injection)
  • 28 Oct 2019 No recent reports of development identified for phase-I development in Tuberculosis(Prevention, In volunteers) in Finland (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top